Skip to main content
NCBI home page
Clinical Molecular Pathology logoLink to Clinical Molecular Pathology
. 1996 Oct;49(5):M256–M267. doi: 10.1136/mp.49.5.m256

Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications

K F Yoong 1, D H Adams 1
PMCID: PMC408070  PMID: 16696086

Full text

PDF
M256

Images in this article

M257Image
on p.M257
M257Image
on p.M257

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D. H., Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet. 1994 Apr 2;343(8901):831–836. doi: 10.1016/s0140-6736(94)92029-x. [DOI] [PubMed] [Google Scholar]
  2. Allison J. P., Hurwitz A. A., Leach D. R. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol. 1995 Oct;7(5):682–686. doi: 10.1016/0952-7915(95)80077-8. [DOI] [PubMed] [Google Scholar]
  3. Bakker A. B., Schreurs M. W., de Boer A. J., Kawakami Y., Rosenberg S. A., Adema G. J., Figdor C. G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994 Mar 1;179(3):1005–1009. doi: 10.1084/jem.179.3.1005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barnd D. L., Lan M. S., Metzgar R. S., Finn O. J. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A. 1989 Sep;86(18):7159–7163. doi: 10.1073/pnas.86.18.7159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barth R. J., Jr, Bock S. N., Mulé J. J., Rosenberg S. A. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J Immunol. 1990 Feb 15;144(4):1531–1537. [PubMed] [Google Scholar]
  6. Barth R. J., Jr, Mulé J. J., Asher A. L., Sanda M. G., Rosenberg S. A. Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-gamma and tumor necrosis factor. J Immunol Methods. 1991 Jul 5;140(2):269–279. doi: 10.1016/0022-1759(91)90380-x. [DOI] [PubMed] [Google Scholar]
  7. Belldegrun A., Muul L. M., Rosenberg S. A. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res. 1988 Jan 1;48(1):206–214. [PubMed] [Google Scholar]
  8. Boon T., Gajewski T. F., Coulie P. G. From defined human tumor antigens to effective immunization? Immunol Today. 1995 Jul;16(7):334–336. doi: 10.1016/0167-5699(95)80149-9. [DOI] [PubMed] [Google Scholar]
  9. Botha J. H., Robinson K. M., Ramchurren N., Reddi K., Norman R. J. Human esophageal carcinoma cell lines: prostaglandin production, biological properties, and behavior in nude mice. J Natl Cancer Inst. 1986 Jun;76(6):1053–1056. [PubMed] [Google Scholar]
  10. Brichard V., Van Pel A., Wölfel T., Wölfel C., De Plaen E., Lethé B., Coulie P., Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993 Aug 1;178(2):489–495. doi: 10.1084/jem.178.2.489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bukowski R. M., Sharfman W., Murthy S., Rayman P., Tubbs R., Alexander J., Budd G. T., Sergi J. S., Bauer L., Gibson V. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res. 1991 Aug 15;51(16):4199–4205. [PubMed] [Google Scholar]
  12. Cardi G., Mastrangelo M. J., Berd D. Depletion of T-cells with the CD4+CD45R+ phenotype in lymphocytes that infiltrate subcutaneous metastases of human melanoma. Cancer Res. 1989 Dec 1;49(23):6562–6565. [PubMed] [Google Scholar]
  13. Chen L., McGowan P., Ashe S., Johnston J., Li Y., Hellström I., Hellström K. E. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994 Feb 1;179(2):523–532. doi: 10.1084/jem.179.2.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cianciolo G. J., Copeland T. D., Oroszlan S., Snyderman R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science. 1985 Oct 25;230(4724):453–455. doi: 10.1126/science.2996136. [DOI] [PubMed] [Google Scholar]
  15. Coulie P. G., Brichard V., Van Pel A., Wölfel T., Schneider J., Traversari C., Mattei S., De Plaen E., Lurquin C., Szikora J. P. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994 Jul 1;180(1):35–42. doi: 10.1084/jem.180.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Cozzolino F., Torcia M., Carossino A. M., Giordani R., Selli C., Talini G., Reali E., Novelli A., Pistoia V., Ferrarini M. Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response. J Exp Med. 1987 Aug 1;166(2):303–318. doi: 10.1084/jem.166.2.303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Crowley N. J., Slingluff C. L., Jr, Darrow T. L., Seigler H. F. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. Cancer Res. 1990 Feb 1;50(3):492–498. [PubMed] [Google Scholar]
  18. Dillman R. O., Oldham R. K., Barth N. M., Cohen R. J., Minor D. R., Birch R., Yannelli J. R., Maleckar J. R., Sferruzza A., Arnold J. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer. 1991 Jul 1;68(1):1–8. doi: 10.1002/1097-0142(19910701)68:1<1::aid-cncr2820680102>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  19. Ditonno P., Tso C. L., Sakata T., deKernion J. B., Belldegrun A. Regulatory effects of interleukin-7 on renal tumor infiltrating lymphocytes. Urol Res. 1992;20(3):205–210. doi: 10.1007/BF00299718. [DOI] [PubMed] [Google Scholar]
  20. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539–3543. doi: 10.1073/pnas.90.8.3539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ebato M., Nitta T., Yagita H., Sato K., Okumura K. Shared amino acid sequences in the ND beta N and N alpha regions of the T cell receptors of tumor-infiltrating lymphocytes within malignant glioma. Eur J Immunol. 1994 Dec;24(12):2987–2992. doi: 10.1002/eji.1830241210. [DOI] [PubMed] [Google Scholar]
  22. Fallarino F., Uyttenhove C., Boon T., Gajewski T. F. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol. 1996 Feb 1;156(3):1095–1100. [PubMed] [Google Scholar]
  23. Farace F., Angevin E., Vanderplancke J., Escudier B., Triebel F. The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration. Int J Cancer. 1994 Dec 15;59(6):752–755. doi: 10.1002/ijc.2910590607. [DOI] [PubMed] [Google Scholar]
  24. Finke J. H., Rayman P., Hart L., Alexander J. P., Edinger M. G., Tubbs R. R., Klein E., Tuason L., Bukowski R. M. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):91–104. doi: 10.1097/00002371-199402000-00002. [DOI] [PubMed] [Google Scholar]
  25. Finke J. H., Tubbs R., Connelly B., Pontes E., Montie J. Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann N Y Acad Sci. 1988;532:387–394. doi: 10.1111/j.1749-6632.1988.tb36356.x. [DOI] [PubMed] [Google Scholar]
  26. Finke J. H., Zea A. H., Stanley J., Longo D. L., Mizoguchi H., Tubbs R. R., Wiltrout R. H., O'Shea J. J., Kudoh S., Klein E. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993 Dec 1;53(23):5613–5616. [PubMed] [Google Scholar]
  27. Freedman R. S., Tomasovic B., Templin S., Atkinson E. N., Kudelka A., Edwards C. L., Platsoucas C. D. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Methods. 1994 Jan 3;167(1-2):145–160. doi: 10.1016/0022-1759(94)90084-1. [DOI] [PubMed] [Google Scholar]
  28. Gaugler B., Van den Eynde B., van der Bruggen P., Romero P., Gaforio J. J., De Plaen E., Lethé B., Brasseur F., Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994 Mar 1;179(3):921–930. doi: 10.1084/jem.179.3.921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ghosh P., Komschlies K. L., Cippitelli M., Longo D. L., Subleski J., Ye J., Sica A., Young H. A., Wiltrout R. H., Ochoa A. C. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst. 1995 Oct 4;87(19):1478–1483. doi: 10.1093/jnci/87.19.1478. [DOI] [PubMed] [Google Scholar]
  30. Ghosh P., Sica A., Young H. A., Ye J., Franco J. L., Wiltrout R. H., Longo D. L., Rice N. R., Komschlies K. L. Alterations in NF kappa B/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res. 1994 Jun 1;54(11):2969–2972. [PubMed] [Google Scholar]
  31. Gingras M. C., Roussel E., Roth J. A., Moser R. P. Little expression of cytokine mRNA by fresh tumour-infiltrating mononuclear leukocytes from glioma and lung adenocarcinoma. Cytokine. 1995 Aug;7(6):580–588. doi: 10.1006/cyto.1995.0079. [DOI] [PubMed] [Google Scholar]
  32. Guilloux Y., Viret C., Gervois N., Le Dréan E., Pandolfino M. C., Diez E., Jotereau F. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur J Immunol. 1994 Sep;24(9):1966–1973. doi: 10.1002/eji.1830240905. [DOI] [PubMed] [Google Scholar]
  33. Hald J., Rasmussen N., Claesson M. H. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol Immunother. 1995 Oct;41(4):243–250. doi: 10.1007/BF01516999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Heo D. S., Whiteside T. L., Johnson J. T., Chen K. N., Barnes E. L., Herberman R. B. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Res. 1987 Dec 1;47(23):6353–6362. [PubMed] [Google Scholar]
  35. Heo D. S., Whiteside T. L., Kanbour A., Herberman R. B. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors. J Immunol. 1988 Jun 1;140(11):4042–4049. [PubMed] [Google Scholar]
  36. Ho M., Jaffe R., Miller G., Breinig M. K., Dummer J. S., Makowka L., Atchison R. W., Karrer F., Nalesnik M. A., Starzl T. E. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation. 1988 Apr;45(4):719–727. doi: 10.1097/00007890-198804000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Hsieh C. S., Macatonia S. E., Tripp C. S., Wolf S. F., O'Garra A., Murphy K. M. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993 Apr 23;260(5107):547–549. doi: 10.1126/science.8097338. [DOI] [PubMed] [Google Scholar]
  38. Huang A. Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994 May 13;264(5161):961–965. doi: 10.1126/science.7513904. [DOI] [PubMed] [Google Scholar]
  39. Hérin M., Lemoine C., Weynants P., Vessière F., Van Pel A., Knuth A., Devos R., Boon T. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer. 1987 Mar 15;39(3):390–396. doi: 10.1002/ijc.2910390320. [DOI] [PubMed] [Google Scholar]
  40. Ikeda H., Sato N., Matsuura A., Kikuchi K. Analysis of T-cell receptor V region gene usage of cytotoxic T-lymphocytes and tumor-infiltrating lymphocytes derived from human autologous gastric signet ring cell carcinomas. Cancer Res. 1993 Jul 1;53(13):3078–3084. [PubMed] [Google Scholar]
  41. Itoh K., Platsoucas C. D., Balch C. M. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med. 1988 Oct 1;168(4):1419–1441. doi: 10.1084/jem.168.4.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Rivoltini L., Topalian S. L., Miki T., Rosenberg S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3515–3519. doi: 10.1073/pnas.91.9.3515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Sakaguchi K., Appella E., Yannelli J. R., Adema G. J., Miki T., Rosenberg S. A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6458–6462. doi: 10.1073/pnas.91.14.6458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P. F., Rivoltini L., Yannelli J. R., Appella E., Rosenberg S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994 Jul 1;180(1):347–352. doi: 10.1084/jem.180.1.347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Kawakami Y., Rosenberg S. A., Lotze M. T. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med. 1988 Dec 1;168(6):2183–2191. doi: 10.1084/jem.168.6.2183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Koo A. S., Tso C. L., Shimabukuro T., Peyret C., deKernion J. B., Belldegrun A. Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma. J Immunother (1991) 1991 Oct;10(5):347–354. doi: 10.1097/00002371-199110000-00006. [DOI] [PubMed] [Google Scholar]
  47. Kooi S., Freedman R. S., Rodriguez-Villanueva J., Platsoucas C. D. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res. 1993 Dec;12(6):429–437. [PubMed] [Google Scholar]
  48. Kradin R. L., Boyle L. A., Preffer F. I., Callahan R. J., Barlai-Kovach M., Strauss H. W., Dubinett S., Kurnick J. T. Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother. 1987;24(1):76–85. doi: 10.1007/BF00199837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Kradin R. L., Boyle L. A., Preffer F. I., Callahan R. J., Barlai-Kovach M., Strauss H. W., Dubinett S., Kurnick J. T. Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother. 1987;24(1):76–85. doi: 10.1007/BF00199837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Kradin R. L., Kurnick J. T., Lazarus D. S., Preffer F. I., Dubinett S. M., Pinto C. E., Gifford J., Davidson E., Grove B., Callahan R. J. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet. 1989 Mar 18;1(8638):577–580. doi: 10.1016/s0140-6736(89)91609-7. [DOI] [PubMed] [Google Scholar]
  51. Kudoh S., Stanley J., Edinger M. G., Tubbs R. R., Klein E., Bukowski R. M., Finke J. H. T lymphocytes infiltrating renal cell carcinoma have a reduced expression of transferrin receptor. Int J Cancer. 1994 Aug 1;58(3):369–375. doi: 10.1002/ijc.2910580311. [DOI] [PubMed] [Google Scholar]
  52. Kuppner M. C., Hamou M. F., de Tribolet N. Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas. Cancer Res. 1988 Dec 1;48(23):6926–6932. [PubMed] [Google Scholar]
  53. Kurnick J. T., Kradin R. L., Blumberg R., Schneeberger E. E., Boyle L. A. Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol. 1986 Mar;38(3):367–380. doi: 10.1016/0090-1229(86)90247-3. [DOI] [PubMed] [Google Scholar]
  54. Kägi D., Ledermann B., Bürki K., Seiler P., Odermatt B., Olsen K. J., Podack E. R., Zinkernagel R. M., Hengartner H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 1994 May 5;369(6475):31–37. doi: 10.1038/369031a0. [DOI] [PubMed] [Google Scholar]
  55. Kägi D., Vignaux F., Ledermann B., Bürki K., Depraetere V., Nagata S., Hengartner H., Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994 Jul 22;265(5171):528–530. doi: 10.1126/science.7518614. [DOI] [PubMed] [Google Scholar]
  56. Lee T. Y., Koo A. S., Peyret C., Shimabukuro T., Dekernion J. B., Belldegrun A. The effects of interleukin-6 on tumor-infiltrating lymphocytes derived from human renal cell cancer. J Urol. 1991 Mar;145(3):663–667. doi: 10.1016/s0022-5347(17)38416-1. [DOI] [PubMed] [Google Scholar]
  57. Li Y., McGowan P., Hellström I., Hellström K. E., Chen L. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol. 1994 Jul 1;153(1):421–428. [PubMed] [Google Scholar]
  58. Loeffler C. M., Smyth M. J., Longo D. L., Kopp W. C., Harvey L. K., Tribble H. R., Tase J. E., Urba W. J., Leonard A. S., Young H. A. Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. J Immunol. 1992 Aug 1;149(3):949–956. [PubMed] [Google Scholar]
  59. Lotze M. T., Line B. R., Mathisen D. J., Rosenberg S. A. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol. 1980 Oct;125(4):1487–1493. [PubMed] [Google Scholar]
  60. Mackensen A., Ferradini L., Carcelain G., Triebel F., Faure F., Viel S., Hercend T. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res. 1993 Aug 1;53(15):3569–3573. [PubMed] [Google Scholar]
  61. Marcus S. G., Perry-Lalley D., Mulé J. J., Rosenberg S. A., Yang J. C. The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity. J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):105–112. doi: 10.1097/00002371-199402000-00003. [DOI] [PubMed] [Google Scholar]
  62. Mattes M. J., Thomson T. M., Old L. J., Lloyd K. O. A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int J Cancer. 1983 Dec 15;32(6):717–721. doi: 10.1002/ijc.2910320610. [DOI] [PubMed] [Google Scholar]
  63. McAdam A. J., Pulaski B. A., Harkins S. S., Hutter E. K., Lord E. M., Frelinger J. G. Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells. Int J Cancer. 1995 May 29;61(5):628–634. doi: 10.1002/ijc.2910610508. [DOI] [PubMed] [Google Scholar]
  64. Miescher S., Stoeck M., Qiao L., Barras C., Barrelet L., von Fliedner V. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int J Cancer. 1988 Nov 15;42(5):659–666. doi: 10.1002/ijc.2910420504. [DOI] [PubMed] [Google Scholar]
  65. Miescher S., Whiteside T. L., Carrel S., von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol. 1986 Mar 1;136(5):1899–1907. [PubMed] [Google Scholar]
  66. Mitropoulos D., Kooi S., Rodriguez-Villanueva J., Platsoucas C. D. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma. Clin Exp Immunol. 1994 Aug;97(2):321–327. doi: 10.1111/j.1365-2249.1994.tb06088.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Mizoguchi H., O'Shea J. J., Longo D. L., Loeffler C. M., McVicar D. W., Ochoa A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 1992 Dec 11;258(5089):1795–1798. doi: 10.1126/science.1465616. [DOI] [PubMed] [Google Scholar]
  68. Morgan D. A., Ruscetti F. W., Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976 Sep 10;193(4257):1007–1008. doi: 10.1126/science.181845. [DOI] [PubMed] [Google Scholar]
  69. Mosmann T. R., Cherwinski H., Bond M. W., Giedlin M. A., Coffman R. L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986 Apr 1;136(7):2348–2357. [PubMed] [Google Scholar]
  70. Mosmann T. R., Coffman R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173. doi: 10.1146/annurev.iy.07.040189.001045. [DOI] [PubMed] [Google Scholar]
  71. Mukherji B., Wilhelm S. A., Guha A., Ergin M. T. Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol. 1986 Mar 1;136(5):1888–1892. [PubMed] [Google Scholar]
  72. Muul L. M., Spiess P. J., Director E. P., Rosenberg S. A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol. 1987 Feb 1;138(3):989–995. [PubMed] [Google Scholar]
  73. Nakagomi H., Petersson M., Magnusson I., Juhlin C., Matsuda M., Mellstedt H., Taupin J. L., Vivier E., Anderson P., Kiessling R. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993 Dec 1;53(23):5610–5612. [PubMed] [Google Scholar]
  74. Neckers L. M., Cossman J. Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2. Proc Natl Acad Sci U S A. 1983 Jun;80(11):3494–3498. doi: 10.1073/pnas.80.11.3494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Nitta T., Oksenberg J. R., Rao N. A., Steinman L. Predominant expression of T cell receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma. Science. 1990 Aug 10;249(4969):672–674. doi: 10.1126/science.2382141. [DOI] [PubMed] [Google Scholar]
  76. Ohmen J. D., Moy R. L., Zovich D., Lieberman A., Wyzykowski R. J., Sullivan L., Modlin R. L., Uyemura K. Selective accumulation of T cells according to T-cell receptor V beta gene usage in skin cancer. J Invest Dermatol. 1994 Dec;103(6):751–757. doi: 10.1111/1523-1747.ep12412288. [DOI] [PubMed] [Google Scholar]
  77. Ostenstad B., Sioud M., Schlichting E., Lea T., Harboe M. Freshly isolated tumour-infiltrating T-lymphocytes have a high cytotoxic potential, as measured by their ability to induce apoptosis in the target cell. Scand J Immunol. 1995 Jan;41(1):42–48. doi: 10.1111/j.1365-3083.1995.tb03531.x. [DOI] [PubMed] [Google Scholar]
  78. Penn I. Tumors arising in organ transplant recipients. Adv Cancer Res. 1978;28:31–61. doi: 10.1016/s0065-230x(08)60645-4. [DOI] [PubMed] [Google Scholar]
  79. Pockaj B. A., Sherry R. M., Wei J. P., Yannelli J. R., Carter C. S., Leitman S. F., Carasquillo J. A., Steinberg S. M., Rosenberg S. A., Yang J. C. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer. 1994 Mar 15;73(6):1731–1737. doi: 10.1002/1097-0142(19940315)73:6<1731::aid-cncr2820730630>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  80. Rabinowich H., Cohen R., Bruderman I., Steiner Z., Klajman A. Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res. 1987 Jan 1;47(1):173–177. [PubMed] [Google Scholar]
  81. Ravaud A., Legrand E., Delaunay M. M., Bussières E., Coulon V., Cany L., Huet S., Verdier D., Kind M., Chomy F. A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma. Br J Cancer. 1995 Feb;71(2):331–336. doi: 10.1038/bjc.1995.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Robb R. J. The suppressive effect of gangliosides upon IL 2-dependent proliferation as a function of inhibition of IL 2-receptor association. J Immunol. 1986 Feb 1;136(3):971–976. [PubMed] [Google Scholar]
  83. Robbins P. F., el-Gamil M., Kawakami Y., Stevens E., Yannelli J. R., Rosenberg S. A. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 1994 Jun 15;54(12):3124–3126. [PubMed] [Google Scholar]
  84. Rosenberg S. A., Packard B. S., Aebersold P. M., Solomon D., Topalian S. L., Toy S. T., Simon P., Lotze M. T., Yang J. C., Seipp C. A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–1680. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  85. Rosenberg S. A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986 Sep 19;233(4770):1318–1321. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  86. Rouvier E., Luciani M. F., Golstein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med. 1993 Jan 1;177(1):195–200. doi: 10.1084/jem.177.1.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Salmi M., Grenman R., Grenman S., Nordman E., Jalkanen S. Tumor endothelium selectively supports binding of IL-2-propagated tumor-infiltrating lymphocytes. J Immunol. 1995 Jun 1;154(11):6002–6012. [PubMed] [Google Scholar]
  88. Salvi S., Segalla F., Rao S., Arienti F., Sartori M., Bratina G., Caronni E., Anichini A., Clemente C., Parmiani G. Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. Cancer Res. 1995 Aug 1;55(15):3374–3379. [PubMed] [Google Scholar]
  89. Schwartz R. H. A cell culture model for T lymphocyte clonal anergy. Science. 1990 Jun 15;248(4961):1349–1356. doi: 10.1126/science.2113314. [DOI] [PubMed] [Google Scholar]
  90. Schøller J., thor Straten P., Birck A., Siim E., Dahlström K., Drzewiecki K. T., Zeuthen J. Analysis of T cell receptor alpha beta variability in lymphocytes infiltrating melanoma primary tumours and metastatic lesions. Cancer Immunol Immunother. 1994 Oct;39(4):239–248. doi: 10.1007/BF01525987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Shimizu Y., Iwatsuki S., Herberman R. B., Whiteside T. L. Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors. Cancer Immunol Immunother. 1991;32(5):280–288. doi: 10.1007/BF01789045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Shimizu Y., Weidmann E., Iwatsuki S., Herberman R. B., Whiteside T. L. Characterization of human autotumor-reactive T-cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma. Cancer Res. 1991 Nov 15;51(22):6153–6162. [PubMed] [Google Scholar]
  93. Sim G. K. Intraepithelial lymphocytes and the immune system. Adv Immunol. 1995;58:297–343. doi: 10.1016/s0065-2776(08)60622-7. [DOI] [PubMed] [Google Scholar]
  94. Skornick Y., Topalian S., Rosenberg S. A. Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor. J Biol Response Mod. 1990 Aug;9(4):431–438. [PubMed] [Google Scholar]
  95. Smith K. A. Interleukin-2: inception, impact, and implications. Science. 1988 May 27;240(4856):1169–1176. doi: 10.1126/science.3131876. [DOI] [PubMed] [Google Scholar]
  96. Snyderman C. H., Heo D. S., Chen K., Whiteside T. L., Johnson J. T. T-cell markers in tumor-infiltrating lymphocytes of head and neck cancer. Head Neck. 1989 Jul-Aug;11(4):331–336. doi: 10.1002/hed.2880110408. [DOI] [PubMed] [Google Scholar]
  97. Spiess P. J., Yang J. C., Rosenberg S. A. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst. 1987 Nov;79(5):1067–1075. [PubMed] [Google Scholar]
  98. Stewart T., Tsai S. C., Grayson H., Henderson R., Opelz G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet. 1995 Sep 23;346(8978):796–798. doi: 10.1016/s0140-6736(95)91618-0. [DOI] [PubMed] [Google Scholar]
  99. Street N. E., Schumacher J. H., Fong T. A., Bass H., Fiorentino D. F., Leverah J. A., Mosmann T. R. Heterogeneity of mouse helper T cells. Evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells. J Immunol. 1990 Mar 1;144(5):1629–1639. [PubMed] [Google Scholar]
  100. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993 Dec 17;75(6):1169–1178. doi: 10.1016/0092-8674(93)90326-l. [DOI] [PubMed] [Google Scholar]
  101. Svennevig J. L., Lunde O. C., Holter J., Bjørgsvik D. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer. 1984 Mar;49(3):375–377. doi: 10.1038/bjc.1984.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Takagi S., Chen K., Schwarz R., Iwatsuki S., Herberman R. B., Whiteside T. L. Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2. Cancer. 1989 Jan 1;63(1):102–111. doi: 10.1002/1097-0142(19890101)63:1<102::aid-cncr2820630117>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  103. Tang D. G., Honn K. V. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis. 1994;14(1-6):109–122. [PubMed] [Google Scholar]
  104. Topalian S. L., Rivoltini L., Mancini M., Markus N. R., Robbins P. F., Kawakami Y., Rosenberg S. A. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9461–9465. doi: 10.1073/pnas.91.20.9461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Topalian S. L., Solomon D., Rosenberg S. A. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989 May 15;142(10):3714–3725. [PubMed] [Google Scholar]
  106. Townsend A., Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol. 1989;7:601–624. doi: 10.1146/annurev.iy.07.040189.003125. [DOI] [PubMed] [Google Scholar]
  107. Treisman J., Hwu P., Yannelli J. R., Shafer G. E., Cowherd R., Samid D., Rosenberg S. A. Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid. Cell Immunol. 1994 Jul;156(2):448–457. doi: 10.1006/cimm.1994.1189. [DOI] [PubMed] [Google Scholar]
  108. Tso C. L., Duckett T., deKernion J. B., Belldegrun A. S. Modulation of tumor-infiltrating lymphocytes derived from human renal cell carcinoma by interleukin-4. J Immunother (1991) 1992 Aug;12(2):82–89. doi: 10.1097/00002371-199208000-00002. [DOI] [PubMed] [Google Scholar]
  109. Underwood J. C. Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br J Cancer. 1974 Dec;30(6):538–548. doi: 10.1038/bjc.1974.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Vijayasaradhi S., Bouchard B., Houghton A. N. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med. 1990 Apr 1;171(4):1375–1380. doi: 10.1084/jem.171.4.1375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Vitolo D., Letessier E. M., Johnson J. T., Whiteside T. L. Immunologic effector cells in head and neck cancer. J Natl Cancer Inst Monogr. 1992;(13):203–208. [PubMed] [Google Scholar]
  112. Vitolo D., Zerbe T., Kanbour A., Dahl C., Herberman R. B., Whiteside T. L. Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer. 1992 Jun 19;51(4):573–580. doi: 10.1002/ijc.2910510412. [DOI] [PubMed] [Google Scholar]
  113. Wang Q., Stanley J., Kudoh S., Myles J., Kolenko V., Yi T., Tubbs R., Bukowski R., Finke J. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J Immunol. 1995 Aug 1;155(3):1382–1392. [PubMed] [Google Scholar]
  114. Wang R. F., Robbins P. F., Kawakami Y., Kang X. Q., Rosenberg S. A. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med. 1995 Feb 1;181(2):799–804. doi: 10.1084/jem.181.2.799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Weidmann E., Elder E. M., Trucco M., Lotze M. T., Whiteside T. L. Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. Int J Cancer. 1993 May 28;54(3):383–390. doi: 10.1002/ijc.2910540306. [DOI] [PubMed] [Google Scholar]
  116. Weidmann E., Logan T. F., Yasumura S., Kirkwood J. M., Trucco M., Whiteside T. L. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res. 1993 Oct 15;53(20):4745–4749. [PubMed] [Google Scholar]
  117. Weidmann E., Whiteside T. L., Giorda R., Herberman R. B., Trucco M. The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma. Cancer Res. 1992 Nov 1;52(21):5913–5920. [PubMed] [Google Scholar]
  118. Weiss L. Cell adhesion molecules: a critical examination of their role in metastasis. Invasion Metastasis. 1994;14(1-6):192–197. [PubMed] [Google Scholar]
  119. Whiteside T. L., Miescher S., Hurlimann J., Moretta L., von Fliedner V. Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas. Cancer Immunol Immunother. 1986;23(3):169–178. doi: 10.1007/BF00205646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Whiteside T. L., Miescher S., Hurlimann J., Moretta L., von Fliedner V. Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int J Cancer. 1986 Jun 15;37(6):803–811. doi: 10.1002/ijc.2910370602. [DOI] [PubMed] [Google Scholar]
  121. Whiteside T. L., Miescher S., MacDonald H. R., Von Fliedner V. Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients. J Immunol Methods. 1986 Jun 24;90(2):221–233. doi: 10.1016/0022-1759(86)90079-7. [DOI] [PubMed] [Google Scholar]
  122. Whiteside T. L. Tumor-infiltrating lymphocytes as antitumor effector cells. Biotherapy. 1992;5(1):47–61. doi: 10.1007/BF02194785. [DOI] [PubMed] [Google Scholar]
  123. Wolf G. T., Hudson J. L., Peterson K. A., Miller H. L., McClatchey K. D. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg. 1986 Sep;95(2):142–152. doi: 10.1177/019459988609500203. [DOI] [PubMed] [Google Scholar]
  124. Wrann M., Bodmer S., de Martin R., Siepl C., Hofer-Warbinek R., Frei K., Hofer E., Fontana A. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J. 1987 Jun;6(6):1633–1636. doi: 10.1002/j.1460-2075.1987.tb02411.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Wölfel T., Van Pel A., Brichard V., Schneider J., Seliger B., Meyer zum Büschenfelde K. H., Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 1994 Mar;24(3):759–764. doi: 10.1002/eji.1830240340. [DOI] [PubMed] [Google Scholar]
  126. Yamamoto K., Masuko K., Takahashi S., Ikeda Y., Kato T., Mizushima Y., Hayashi K., Nishioka K. Accumulation of distinct T cell clonotypes in human solid tumors. J Immunol. 1995 Feb 15;154(4):1804–1809. [PubMed] [Google Scholar]
  127. Yamaue H., Kashmiri S. V., De Filippi R., Nieroda C., Yannelli J. R., Tsang K. Y., Schlom J. Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene. J Immunother Emphasis Tumor Immunol. 1994 Nov;16(4):262–274. doi: 10.1097/00002371-199411000-00002. [DOI] [PubMed] [Google Scholar]
  128. Yannelli J. R. The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer. J Immunol Methods. 1991 May 17;139(1):1–16. doi: 10.1016/0022-1759(91)90345-g. [DOI] [PubMed] [Google Scholar]
  129. Yasumura S., Weidmann E., Hirabayashi H., Johnson J. T., Herberman R. B., Whiteside T. L. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck. Int J Cancer. 1994 May 1;57(3):297–305. doi: 10.1002/ijc.2910570302. [DOI] [PubMed] [Google Scholar]
  130. Yoo Y. K., Heo D. S., Hata K., Van Thiel D. H., Whiteside T. L. Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. Gastroenterology. 1990 Feb;98(2):259–268. [PubMed] [Google Scholar]
  131. Yron I., Wood T. A., Jr, Spiess P. J., Rosenberg S. A. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol. 1980 Jul;125(1):238–245. [PubMed] [Google Scholar]
  132. Zakut R., Topalian S. L., Kawakami Y., Mancini M., Eliyahu S., Rosenberg S. A. Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. Cancer Res. 1993 Jan 1;53(1):5–8. [PubMed] [Google Scholar]
  133. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991 Dec 13;254(5038):1643–1647. doi: 10.1126/science.1840703. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES